- Poster presentation
- Open Access
Description of the localized scleroderma subgroup of CARRAnet
© Wu et al; licensee BioMed Central Ltd. 2012
- Published: 13 July 2012
- Physician Global Assessment
- Fibrosing Skin
- Localize Scleroderma
- Skin Induration
- Rheumatologic Disorder
Localized scleroderma (LS) is a chronic inflammatory and fibrosing skin disease, more common in children. We present baseline data on the juvenile LS (jLS) cohort from the CARRAnet observational registry of pediatric rheumatologic disorders.
We performed a cross-sectional baseline analysis of registry data for jLS.
Abnormal creatine kinase
Abnormal CNS imaging
Abnormal GI study
Longterm daily corticosteroids
jLS is reported more frequently in females and Caucasians in the CARRA Registry. LiScl is the most common lesion subtype, representing 77% of all patients. 45% of the jLS cohort is ANA positive. Subcutaneous and oral MTX, MMF, and pulse CS are the most common medications used for treatment. There is an almost 2 year delay in referral to pediatric rheumatology. There is significant morbidity associated with jLS with 30% reporting limitation in functional capacity.
Eveline Wu: None; Egla C. Rabinovich: None; Kathryn S. Torok: None; Suzanne C. Li: None; Robert C. Fuhlbrigge: None; CARRAnet Investigators: None.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.